Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Savara ( (SVRA) ) has shared an update.
On March 26, 2025, Savara announced a loan agreement with Hercules Capital for up to $200 million, aimed at strengthening its financial position following the submission of a Biologics License Application to the FDA for MOLBREEVI, a potential first-in-class therapy for aPAP. The agreement includes an initial $30 million to refinance existing debt, with additional funds contingent on FDA approval and other milestones, supporting Savara’s efforts to commercialize MOLBREEVI in the U.S. and Europe.
More about Savara
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Its lead program, MOLBREEVI, is in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
YTD Price Performance: -9.77%
Average Trading Volume: 1,013,887
Technical Sentiment Signal: Buy
Current Market Cap: $475.4M
See more insights into SVRA stock on TipRanks’ Stock Analysis page.